Применение ботулинического токсина типа A при ревматических заболеваниях
https://doi.org/10.14412/1996-7012-2021-5-108-113
Аннотация
В статье представлен анализ современных данных об эффективности антиноцицептивного действия ботулинического токсина типа А (БТА) при ревматических заболеваниях (РЗ). Обсуждены перспективы использования БТА в терапии боли при разных РЗ. Поиск публикаций проводился в базах данных Medline, Pubmed, Cochrane Library. Как показал анализ данных литературы, БТА может стать дополнительным методом лечения боли при многих РЗ.
При поддержке: Работа выполнена в рамках научной исследовательской работы «Инновационные технологии диагностики и лечения системных заболеваний соединительной ткани» (ИКБРС 0397-2020-0006).
Об авторах
О. Н. Егорова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Ольга Николаевна Егорова
115522, Москва, Каширское шоссе, 34А
Б. С. Белов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
Е. Г. Сажина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi: 10.1016/j.ejpain.2005.06.009.Epub 2005 Aug 10.
2. Екушева ЕВ. Коморбидный пациент с хроническим болевым синдромом. Русский медицинский журнал. 2019;(9):44-8.
3. http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf
4. Насонова ВА, Каратеев АЕ. Симптоматическая терапия боли при ревматических заболеваниях: место ацеклофенака. Современная ревматология. 2009;3(3):58-65.
5. Zhai S, Huang B, Yu K. The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis. J Int Med Res. 2019 Dec 29: 300060519895868. doi: 10.1177/0300060519895868.
6. Костенко ЕВ, Коновалова ЗН, Орлова ОР, Хатькова СЕ. Ботулотоксин при болевых синдромах. Медицинский совет. 2018;(1):58-63.
7. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. doi: 10.1016/j.neuro.2005.01.017. Epub 2005 Jul 5.
8. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 Jan;33(1):48-56. doi: 10.1002/ana.410330109.
9. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001 Apr;91(3): 195-9. doi: 10.1016/S0304-3959(01)00292-5
10. Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001 Oct;2(10):1649-54. doi: 10.1517/14656566.2.10.1649.
11. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. Jul-Aug 2003;43 Suppl 1: S9-15. doi: 10.1046/j.1526-4610.43.7s.3.x.
12. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006 Jun;122(3):315-25. doi: 10.1016/j.pain.2006.04.014. Epub 2006 May 4.
13. Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009 Jan;141(1-2):60-9. doi: 10.1016/j.pain.2008.10.005. Epub 2008 Nov 11.
14. Артемьев ДВ, Орлова ОР, Моренкова АЭ. Использование ботокса в медицинской практике. Неврологический журнал.2000;5(4):46-51.
15. Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 2013 Oct;81(10): 3894-902. doi: 10.1128/IAI.00536-13. Epub 2013 Aug 5.
16. Pier CL, Chen C, Tepp WH, et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011 Jan 3;585(1):199-206. doi: 10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.
17. Akaike N, Shin MC, Wakita M, et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol. 2013 Feb 15;591(4):1031-43. doi: 10.1113/jphysiol.2012.242131. Epub 2012 Oct 29.
18. Mahowald ML, Singh JA, Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006 Apr;9(2-3):179-88. doi: 10.1007/BF03033937.
19. Singh JA, Mahowald ML. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Joint Bone Spine. 2009 Mar;76(2):190-4. doi: 10.1016/j.jbspin.2008.05.006. Epub 2008 Oct 25.
20. Singh JA, Mahowald ML, Kushnaryov A, et al. Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. J Clin Rheumatol. 2009 Feb;15(1):35-8. doi: 10.1097/RHU.0b013e3181953b14.
21. Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009 May;153(5):205-16. doi: 10.1016 /j.trsl.2009.02.004. Epub 2009 Mar 13.
22. Kidd BL. Osteoarthritis and joint pain. Pain. 2006 Jul;123(1-2):6-9. doi: 10.1016/j.pain.2006.04.009. Epub 2006 May 22.
23. Martell-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. doi: 10.1038/nrdp.2016.72.
24. Ivanusic JJ. Molecular Mechanisms That Contribute to Bone Marrow Pain. Front Neurol. 2017 Sep 11;8:458. doi: 10.3389/fneur.2017.00458. eCollection 2017.
25. Khenioui H, Houvenagel E, Catanzariti JF, et al. Usefulness of intra-articular botulinum toxin injections. A systematic review. Joint Bone Spine. 2016 Mar;83(2):149-54. doi: 10.1016/j.jbspin.2015.10.001. Epub 2015 Nov 29.
26. Schaible HG, Ebersberger A, von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002 Jun;966: 343-54. doi: 10.1111/j.1749-6632.2002.tb04234.x.
27. Hsieh LF, Wu CW, Chou CC, et al. Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PM R. 2016 Dec;8(12): 1127-35. doi: 10.1016/j.pmrj.2016.05.009. Epub 2016 May 19.
28. Chou CL, Lee SH, Lu SY, et al. Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J Chin Med Assoc. 2010 Nov; 73(11):573-80. doi: 10.1016/S1726-4901(10)70126-X.
29. Cinone N, Letizia S, Santoro L, et al. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature. J Pain Res. 2018 Jun 25;11:1239-45. doi: 10.2147/JPR.S159700.eCollection 2018.
30. Joo YJ, Yoon SJ, Kim CW. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann Rehabil Med. 2013 Apr;37(2):208-14. doi: 10.5535/arm.2013.37.2.208. Epub 2013 Apr 30.
31. Sun SF, Hsu CW, Lin HS, et al. Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial. J Foot Ankle Res. 2014 Feb 6;7(1):9. doi: 10.1186/1757-1146-7-9.
32. Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010 Nov; 37(11):2377-86. doi: 10.3899/jrheum.100336.Epub 2010 Sep 1.
33. Arendt-Nielsen L, Jiang G, De Gryse R, Turkel C. Intra-articular onabotulinumtoxin A in osteoarthritis knee pain: Effect on human mechanistic pain biomarkers and clinical pain. Scand J Rheumatol. 2017 Jul; 46(4):303-16. doi: 10.1080/03009742.2016.1203988. Epub 2016 Oct 13.
34. McAlindon TE, Schmidt U, Bugarin D, et al. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis Cartilage. 2018 Oct;26(10): 1291-9. doi: 10.1016/j.joca.2018.05.001. Epub 2018 May 9.
35. Плотникова ЕВ, Елькин ВД, Миронов АН и др. Экпериментальное обоснование к использованию в косметической практике нового отечественного иммунобиологического препарата с миорелаксатным действием «релатокс». Биология и экпериментальная медицина. 2011; XXVIII(4):125-30.
36. Batifol D. Different types of injection in temporomandibular disorders (TMD) treatment. Rev Stomatol Chir Maxillofac Chir Orale. 2016 Sep;117(4):256-8. doi: 10.1016/j.revsto.2016.07.005. Epub 2016 Aug 23.
37. Sycha T, Graninger M, Auff E, Shinider P. Botulinum toxin in the treatment of Raynaud phenomenon: A pilot study. Eur J Clin Invest. 2004 Apr;34(4):312-3. doi: 10.1111/j.1365-2362.2004.01324.x.
38. Asad U, Austin B, Tarbox M, Paulger B. Botulinum toxin in the long-term treatment of refractory Raynaud's phenomenon. J Drugs Dermatol. 2019 Sep 1;18(9):943-5.
39. Smith L, Polsky D, Franks AG Jr. Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol. 2012 Apr; 148(4):426-8. doi: 10.1001/archdermatol.2011.1144.
40. Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin. Plast Reconstr Surg. 2007 Jan;119(1):217-26. doi: 10.1097/01.prs.0000244860.00674.57.
41. Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 Dec;35(12):2085-92. doi: 10.1016/j.jhsa.2010.09.019.
42. Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017 Aug;69(8):1661-9. doi: 10.1002/art.40123. Epub 2017 Jun 26.
43. Serri J, Legre R, Veit V, et al. Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013 Dec;58(6): 658-62. doi: 10.1016/j.anplas.2011.11.001.Epub 2011 Dec 26.
44. Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016 Jan;43(1): 56-62. doi: 10.1111/1346-8138.13030. Epub 2015 Jul 15.
45. Medina S, Gomez-Zubiaur A, Valdeolivas-Casillas N, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study. Eur J Rheumatol. 2018 Dec;5(4):224-9. doi: 10.5152/eurjrheum.2018.18013. Epub 2018 Oct 12.
46. Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi: 10.1038/nrrheum.2012.96. Epub 2012 Jul 10.
47. Wigley FM. Clinical practice Raynaud's phenomenon. N Engl J Med. 2002 Sep 26; 347(13):1001-8. doi: 10.1056/NEJMcp013013.
48. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33. doi: 10.1016/j.pain.2003.10.008.
49. Stone AV, Koman AL, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potencial mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012 Apr;37(4):795-802. doi: 10.1016/j.jhsa.2012.01.021. Epub 2012 Mar 3.
50. Setler P. Therapeutic use of botulinum toxins: back-ground and history. Clin J Pain. Nov-Dec 2002;18(6 Suppl):S119-24. doi: 10.1097/00002508-200211001-00002.
51. O'Neil LM, Palme CE, Riffat F, Mahant N. Botulinum toxin for the management of Sjö gren syndrome-associated recurrent parotitis. J Oral Maxillofac Surg. 2016 Dec; 74(12):2428-30. doi: 10.1016/j.joms.2016.06.169. Epub 2016 Jun 18.
52. Daniel SJ, Diamond M. Botulinum toxin injection: a novel treatment for recurrent cystic parotitis Sjö gren syndrome. Otolaryngol Head Neck Surg. 2011 Jul;145(1):180-1. doi: 10.1177/0194599811398596.
53. Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1997 Sep;24(9):1842-3.
54. Francis IC, Coroneo MT. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1998 Sep;25(9):1859.
Рецензия
Для цитирования:
Егорова ОН, Белов БС, Сажина ЕГ. Применение ботулинического токсина типа A при ревматических заболеваниях. Современная ревматология. 2021;15(5):108-113. https://doi.org/10.14412/1996-7012-2021-5-108-113
For citation:
Egorova ON, Belov BS, Sazhina EG. Use of botulinum toxin type A in rheumatic diseases. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(5):108-113. (In Russ.) https://doi.org/10.14412/1996-7012-2021-5-108-113
Просмотров:
1377
Послать статью по эл. почте 